Roche drug shows promise for less common form of MS

Discuss Ocrelizumab, a monoclonal antibody treatment for MS.
Post Reply
User avatar
MSUK
Family Elder
Posts: 2903
Joined: Wed Oct 14, 2009 2:00 pm
Contact:

Roche drug shows promise for less common form of MS

Post by MSUK » Thu Oct 08, 2015 11:33 pm

Swiss drugmaker Roche has said its experimental treatment for multiple sclerosis performed better in a late-stage clinical trial than a commonly used therapy for the most prevalent form of the condition... Read More - http://www.ms-uk.org/MSnews
MS-UK - http://www.ms-uk.org/

User avatar
CureOrBust
Family Elder
Posts: 3361
Joined: Wed Jul 27, 2005 2:00 pm
Location: Sydney, Australia

Re: Roche drug shows promise for less common form of MS

Post by CureOrBust » Thu Oct 08, 2015 11:48 pm

MSUK wrote:Swiss drugmaker Roche has said its experimental treatment for multiple sclerosis performed better in a late-stage clinical trial than a commonly used therapy for the most prevalent form of the condition... Read More - http://www.ms-uk.org/MSnews
...Roche compared ocrelizumab with a placebo...
:lol: So a "Placebo" is the therapy for PPMS. Ya gotta laugh at the truth.

EricDrake
Family Member
Posts: 41
Joined: Sun May 10, 2015 3:04 am

Re: Roche drug shows promise for less common form of MS

Post by EricDrake » Fri Oct 09, 2015 1:18 pm

CureOrBust wrote:
MSUK wrote:Swiss drugmaker Roche has said its experimental treatment for multiple sclerosis performed better in a late-stage clinical trial than a commonly used therapy for the most prevalent form of the condition... Read More - http://www.ms-uk.org/MSnews
...Roche compared ocrelizumab with a placebo...
:lol: So a "Placebo" is the therapy for PPMS. Ya gotta laugh at the truth.
performed better in a late-stage clinical trial than a commonly used therapy for the most prevalent form of the condition

This part is related to the RRMS trial and they are talking abouth interferon-beta

MSbro
Family Member
Posts: 61
Joined: Sun Apr 26, 2015 4:32 am

Re: Roche drug shows promise for less common form of MS

Post by MSbro » Sat Oct 10, 2015 5:55 am

This part is related to the RRMS trial and they are talking abouth interferon-beta
It's interesting that many of these new MAB drugs are compared in trials to the much older interferon type drugs and found to be "better". But for years there have been a number of articles that state these older drugs (CRABs) don't do much if anything for MS in the long run. So why test against something that really isn't much good for MS in the first place? I guess it's called slick marketing.

Post Reply
  • Similar Topics
    Replies
    Views
    Last post